Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06953518 · ClinicalTrials.gov registry record · NA

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

A NA study, sponsored by Qualia Life Sciences.

Not yet
Registry status
NA
Development phase
40
Enrollment target

NCT06953518 is a NA study that has not yet begun recruiting, run by Qualia Life Sciences. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06953518, a NA study, has not yet begun recruiting, sponsored by Qualia Life Sciences.

NOT YET RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Interventions

  • DIETARY_SUPPLEMENT Qualia Senolytic

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-05-12
Est. Completion 2025-05-18
Phase NA

Sponsor

Qualia Life Sciences

10 total trials

What the Registry Record Tells You About NCT06953518

The ClinicalTrials.gov registry entry for NCT06953518 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qualia Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Qualia Senolytic is the first listed.

NCT06953518 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06953518 about?

NCT06953518 is a clinical study titled "An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines". This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All p...

What is the current status of trial NCT06953518?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-05-12. Estimated completion is 2025-05-18.

What interventions are being tested in trial NCT06953518?

The interventions under investigation include: Qualia Senolytic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06953518?

This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.